Thrombophilia and pregnancy complications

Pathophysiology of Haemostasis and Thrombosis

Volumn 35, Issue 1-2, 2006, Pages

  Brenner, Benjamin ^a  

^a RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Anti coagulant therapy; Coagulation; Pregnancy; Thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; CAUCASIAN; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; INHERITANCE; INTRAUTERINE GROWTH RETARDATION; META ANALYSIS; PATIENT MONITORING; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROPHYLAXIS; PUERPERIUM; RISK FACTOR; SOLUTIO PLACENTAE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOPHILIA; VASCULAR DISEASE;

EID: 33748476517     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093540     Document Type: Conference Paper

References (58)

1. Brenner B. Clinical management of thrombophilia-related placental vascular complications. Blood. 2004 103(11):4003-4009.
2. Bremme K, Ostlund E, Almqvist I, Heinonen K, Blomback M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet Gynecol. 1992;80(1):132-137.
3. Bremme KA. Hemostatic changes in pregnancy. Ballieres Best Pract Res Clin Haematol. 2003(2);16:153-168.
4. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood. 1986;68(4):881-885
5. Cumming AM, Tait RC, Fildes S, Yoong A, Keeney S, Hay CR.. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995;90(3): 725-727.
6. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW.. Haemostasis in normal pregnancy. Thromb Haemost. 1984; 52(2): 176-182.
7. Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, et al. Fibrinolysis in pregnancy: a study of plasminogen activator and inhibitors. Blood. 1987;69(2) 460-466.
8. Giavarina D, Messena G, Dorizzi RM, Soffiati G. Reference interval of D-dimer in pregnant women. Clin Biochem. 2001;34(4): 331-333.
9. Aharon A, Brenner B, Katz T, Miyagi Y, Lanir N. Tissue factor and tissue factor pathway inhibitor levels in trophoblast cells: implications for placental hemostasis. Thromb Haemost. 2004;92(4):776-786.
10. Sanson BJ, Friederich PW, Simioni P, Zanardi S, Hilsman MV, Girolami A, et al. The risk of abortion and stillbirth in autithrombin, protein C, and protein S-deficient women. Thromb Haemost. 1996;75(3): 387-388.
11. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia: report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost. 1995;73(1): 151-161.
12. Sarig G, Hoffman R, Younis J, Lanir N, Blumenfeld Z, Brenner B. Thrombophilia is common in women with pregnancy loss and is associated with late pregnancy wastage. Fertil Steril. 2002;77(2):342-347.
13. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med. 2002;126(11);1304-1318.
14. Brenner BR, Nowak-Gottl U, Kosch A, Manco-Johnson M, Laposata M. Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch Pathol Lab Med. 2002;126(11): 1296-303
15. Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyak K, et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med. 1999;130(9):736-739.
16. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. 1997;97(3):551-554
17. Rey E, Kahn SR, David M, Shrier I. Throbophilic disorders and fetal loss: a meta-analysis. Lancet. 2003;361(9361):901-908.
18. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2000;343(14):1015-1018.
19. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J, et al. Increased fetal loss in women with heritable thrombophilia. Lancet. 1996;348(9032):913-916.
20. Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod. 1999;14(6):1624-1627
21. Brenner B. Thrombophilia and pregnancy loss in first intended pregnancy. J Thromb Haemost. 2005 3(10):2176-7.
22. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, Ripart-Neveu S, Balducchi JP, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost. 2005;3(10):2178-2184.
23. Sanson BJ, Lensing AW, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E, et al. Safety of low molecular weight heparin in pregnancy: a systemic review. Thromb Haemost. 1999;81(5):668-672.
24. Lepercq J, Conard J, Borel-Derlon A, Darmon JY, Boudignat O, Francoual C, et al. Venous thromboembolism during pregnancy: a retrospective of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol. 2001;108(11):1134-1140.
25. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005 Jul 15;106(2):401-407
26. Brenner B, Hoffman R, Blumenfeld Z, Weiner Z, Younis J. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83(5):693-697.
27. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost. 2003;1(3):433-438.
28. Gris JC, Mercier E, Quere I, Lavigne-Lissalde G, Cochery-Nouvellon E, Hoffet M, et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695-3699
29. Brenner B, Hoffman R, Carp H, Dulitsky M, Younis J; LIVE-ENOX Investigators. Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE-ENOX study. J Thromb Haemost. 2005;3(2):227-229.
30. Brenner B, Bar J, Ellis M, Yarom I, Yohai D, Samueloff A; Live-Enox Investigators. Effects of enoxaparin on late pregnancy complications and neonatal outcome in women with recurrent pregnancy loss and thrombophilia: results from the Live-Enox study. Fertil Steril. 2005;84(3):770-773.
31. Martinelli P, Grandone E, Colaizzo D, Paladini D, Scianname N, Margaglione M, et al. Familial thrombophilia and the occurrence of fetal growth restriction. Hematologica. 2001;86(4):428-431.
32. Grandone E, Colaizzo D, Brancaccio V, Ciampa A, Di Minno G, Margaglione M, et al. Low birth weight in neonates of mothers carrying factor V G1691A and factor A 20210 mutations. Hematologica. 2002;87(10):177-181.
33. Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphisms with intrauterine growth restriction. N Engl J Med. 2002;347(1):19-25.
34. Kupfermine MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340(1):9-13.
35. Greer IA. Pathological processes in pregnancy-induced hypertension and intrauterine growth retardation 'an excess of heated blood.' In Greer IA, Turpie AGG, Forbes CD, eds. Haemostasis and Thrombosis in Obstetrics and Gynaecology. London, England: Chapman and Hall; 1992: 163-202.
36. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111(5):649-658.
37. Koga K, Osuga Y, Yoshino O, Hirota Y, Ruimeng X, Hirata T, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. J Clin Endocrin Metabol. 2003;88(5):2348- 2351.
38. Benedetto C, Marozio L, Saslton L, Maula V, Chippa G, Massobrio I. Factor V Leiden and factor II G20210A in preeclampsia and HELLP syndrome. Acta Obstet Gynecol Scand. 2002;81(12):1095-1100.
39. Grandone E, Margaglione M, Colaizzo D, Cappucci G, Paladini D, Martinelli P, et al. Factor V Leiden, C>T MTHFR polymorphism and genetic susceptibility to pre-eclampsia. Thromb Haemost. 1997;77(6):1052-1054.
40. De Groot CJ, Bloemenkamp KW, Duvekot EJ, Helmerhorst FM, Bertina RM, Van Der Meer F, et al. Preeclampsia and genetic risk factors for thrombosis: a case control study. Am J Obstet Gynecol. 1999;181(4):975-980.
41. Morrison ER, Miedzybrodzka ZH, Campbell DM, Haites NE, Wilson BJ, Watson MS, et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost. 2002;87(5):779-785.
42. Mello G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T, et al. Thrombophilia is significantly associated with sever preeclampsia: results of a large-scale, case-controlled study. Hypertension. 2005;46(6):1252-1253.
43. Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, et al. A low molecular weight heparin for the prevention of obstetric complications in women with thrombophilia. Hypertens Preg. 2001;20(1):35-44.
44. Grandone E, Brancaccio V, Colaizzo D, Scianname N, Pavoue G, Di Minno G, et al. Preventing adverse obstetric outcomens in women with genetic thrombophilia. Fertil Steril. 2002;78(2):371-375.
45. Goddijn-Wessel TA, Wouters MG, van de Molen EF, Spuijbroek MD, Steegers-Theunissen RP, Blom HJ, et al. Hyper-homocysteinemia: a risk factor for placental abruption or infarction. Eur J Ostet Gynecol Reprod Biol. 1996;66(1):23-29.
46. Vollset SE, Refsum H, Irgens LM, Emblem BM, Tverdal A, Gjessing HK, et al. Plasma total homocysteine pregnancy complications and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000;71(4):962-968.
47. Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril. 2000;74(6):1196-1199.
48. Gris JC, Quere I, Monpeyroux F, Mercier E, Ripart-Neveu S, Tailland ML, et al. Case control study of the frequency of thrombophiilc disorders in couples with late foetal loss and no thrombotic antecedent - the Nimes Obstetricians and Haematologists Study 5 (NOHA5). Thromb Haemost. 1999;81(6):891-899.
49. Wiener-Megnagi Z, Ben-Shlomo I, Goldberg Y, Shalev E. Resistance to activated protein C and the Leiden mutation: high prevalence in patients with abruptio placentae. Am J Obstet Gynecol. 1998;179 (6 Pt 1):1565-1567.
50. Prochazka M, Happach C, Marsal K, Dahlback B, Lindqvist PG. Factor V Leiden in pregnancies complicated by placental abruption. Br J Obstet Gynaecol. 2003;110(5):462-466.
51. Aharon A, Lanir N, Drugan A, Brenner B. Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment. J Thromb Haemost. 2005;3(10):2355-2357.
52. Sarig G, Blumenfeld Z, Leiba R, Lanir N, Brenner B. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss. Thromb Haemost. 2005;94(5):980-985.
53. Rai R, Cohen H, Dave M, Regan L, Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. Br Med J. 1997;314(7076):253-257.
54. Franchi F, Biguzzi E, Cetin I, Facchetti F, Radaelli T, Bozzo M, et al. Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss. Br J Haematol. 2001;114(3):641-646.
55. Laude I, Rongieres-Bertrand C, Boyer-Neumann C, Wolf M, Mairovitz V, Hugel B, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost. 2001;85(1):18-21.
56. Greer IA. Procoagulant microparticles: new insights and opportunities in pregnancy loss? Thromb Haemost. 2001;85(1):3-4.
57. Sarig G, Lanir N, Hoffman R, Brenner B. Protein C global assay in the evaluation of women with diopathic pregnancy loss. Thromb Haemost. 2002;88(1):32-36.
58. Sood R, Kalloway S, Mast AE, Hillard CJ, Weiler H. Feto-maternal cross-talk in the placental vascular bed: control of coagulation by trophoblast cells. Blood. 2005 Dec 27; [Epub ahead of print]. ahead of print].